Back to Authors

Witzig, T.E.

0000-0002-4215-6500

Mayo Clinic

Mayo Clinic

Citations 97

Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma
Ramsower, Colleen , Wright, George W. , Cerhan, James R. , Maurer, Matthew J. , Mwangi, Raphael , Novak, Anne J. , Link, Brian K. , Witzig, Thomas E. , Smith, Sonali M. , Friedberg, Jonathan W. , Rimsza, Lisa M. , Witzig, T.E. , Ramsower, Colleen A , Wright, George , Cerhan, James R , Maurer, Matthew , Rosenthal, Allison , Novak, Anne J , Link, Brian K , Kridel, Robert , Shadman, Mazyar , Smith, Sonali M , Friedberg, Jonathan W , Scott, David W , Steidl, Christian , Rimsza, Lisa M , Li, Hongli , Habermann, Thomas M. , LeBlanc, Michael , Shadman, Mazyar , Scott, David W. , Steidl, Christian

Blood Advances | September 18, 2025 | Volume: 9 | Issue: 24 | Pages: 6443-6454

10.1182/bloodadvances.2025016827 Get It

Abstract Although follicular lymphoma (FL) typically follows an indolent course, patients with FL who experience early events, such as transformation or progression, have increased risk of death related to lymphoma. The FL24Cx is an algorithm based on a 45-target gene expression profiling (GEP) assay, which was developed and trained using 265 formalin-fixed, paraffin-embedded tissue samples on a reliable platform to predict, at the time of diagnosis, whether a patient will experience an event within 24 months. The modeling also confirmed and relied upon previously reported synergy between immune response (IR) gene expression signatures IR1 and IR2. Once locked, the 5-factor logistic regression FL24Cx model was independently validated in a retrospectively assessed cohort of 232 patients from 2 immunochemotherapy-treated arms of SWOG Cancer Research Network S0016 phase 3 clinical trial, in which it assigned 169 patients to the low-risk group with 29 events before 24 months (17.2%) and 63 patients to the high-risk group with 24 events before 24 months (38.1%). The relative risk of an event within 24 months after registration among patients who were classified into the high-risk group relative to patients who were classified into the low-risk group was 2.2 (95% confidence interval, 1.41 to 3.51). An up-front GEP biomarker, such as the FL24Cx, rigorously validated in a clinical laboratory and with a clinically relevant turnaround time, could identify and steer enrollment of patients at high risk for early events in clinical trials, thus enabling timely interpretation of such trials and increasing the pace of innovation.
Multi‐Institutional Study of ALK ‐Positive Large B‐Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies
Atallah‐Yunes, Suheil Albert , Nze, Chijioke , King, Rebecca L. , Alderuccio, Juan Pablo , Watkins, Marcus P. , Easwar, Neela, Yamshon, Samuel , Ravindra, Aditya, Farooq, Umar , Rojas-Neira, Estela, Ayers, Amy , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Flowers, Christopher R. , Easton, Neil , Nze, Chijioke C , Rees, Matthew James , Alderuccio, Juan Pablo , Watkins, Marcus , Yamshon, Samuel , Rosenthal, Allison , Habermann, Thomas , Witzig, T.E. , Ansell, Stephen M , Wang, Yucai , Easton, Neela , Atallah-Yunes, Albert , Rees, Matthew J. , Kahl, Brad S. , Ravindra, Aditya , Farooq, Umar, Muñoz, Javier , Moustafa, Muhamad Alhaj , Habermann, Thomas M. , Witzig, Thomas E. , Koff, Jean L. , Wang, Yucai

American Journal of Hematology | September 3, 2025 | Volume: 100 | Issue: 12 | Pages: 2185-2194

10.1002/ajh.70058 Get It

ABSTRACT Anaplastic lymphoma kinase‐positive large B‐cell lymphoma (ALK+ LBCL) is a rare, aggressive subtype of diffuse large B‐cell lymphoma with poor outcomes using standard chemotherapy. In this multi‐institutional retrospective study, we analyzed 39 cases of ALK+ LBCL identified at six US academic centers from 2002 to 2024, with treatment including conventional cytotoxic regimens in frontline and biologically informed and nonchemotherapy‐based strategies in the relapsed setting. Ninety‐two percent of patients received frontline anthracycline‐based chemotherapy; 43% received intensified regimens, and 15% underwent upfront autologous stem cell transplantation (ASCT). Despite these approaches, outcomes remained poor. At a median follow‐up of 5.4 years, median event‐free survival (EFS) was 0.6 years (95% CI, 0.4–0.9), and median overall survival (OS) was 1.5 years (95% CI, 1.3–NR). One‐ and five‐year EFS rates were 28% and 17%, while corresponding OS rates were 72% and 42%, respectively. Advanced stage and high IPI scores were associated with inferior outcomes. Twelve patients received ALK inhibitors, with alectinib showing more durable responses than crizotinib. Lenalidomide and immune checkpoint inhibitors also demonstrated activity, including durable complete responses. Five patients underwent allogeneic stem cell transplantation, with three achieving sustained remission. In conclusion, our findings highlight the limited benefit of chemotherapy, even when intensified or followed by ASCT, and support the integration of biologically targeted therapies, which may have contributed to improved OS in our cohort compared to historical outcomes. Prospective, collaborative studies are needed to better understand disease biology and define optimal use of modern therapies in this rare lymphoma.
Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes
Tawfiq, R., Spears, Grant M. , Young, Jason R., Mahowald, Madeline , Tobin, W. Oliver , Patgunarajah, Ubenthira, Ruan, Gordon , Yi, Dongni , Zanwar, Saurabh , Gruber, Lucinda , Ravindran, Aishwarya , Sartori‐Valinotti, Julio C. , Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Dasari, Surendra , Abeykoon, Jithma P. , Tawfiq, Reema K , Mahowald, Madeline K , Ruan, Gordon J , Acosta-Medina, Aldo A , Ravindran, Aishwarya , Shah, Mithun V , Bennani, N Nora , Moustafa, Muhamad Alhaj , Hilal, Talal , Sartori-Valinotti, J C , Vassallo, Robert , Ryu, Jay H , Witzig, T.E. , Goyal, Guarav , Abeykoon, Jithma P , Tobin, W Oliver , Rech, Karen L. , Koster, Matthew J. , Acosta‐Medina, Aldo A. , Shah, Meera , Bennani, N. Nora , Moustafa, Muhamad Alhaj , Hilal, Talal , Witzig, Thomas E. , Go, Ronald S. , Goyal, Gaurav

Blood Advances | August 28, 2025 | Volume: 9 | Issue: 23 | Pages: 5988-6000

10.1182/bloodadvances.2025016608 Get It

Abstract Erdheim-Chester disease (ECD) is a rare systemic histiocytic neoplasm, with cardiac morbidities, including cardiovascular (CV) risk factors and cardiac conditions, playing a significant yet poorly understood role in the disease burden. This study evaluated the prevalence, characteristics, and prognosis of ECD in patients with (ECD-C) and without cardiac involvement (ECD-noC) and compared the burden of cardiac morbidities with matched controls. Patients diagnosed with ECD between 1990 and 2021 at a tertiary center were included, with cardiac involvement centrally assessed using radiographic studies. Cardiac morbidities were compared with a control group without ECD, matched for age, sex, body mass index, and smoking history. Among 104 patients with ECD, 39 (37%) had cardiac involvement. Patients with ECD-C had higher rates of hypertension (67% vs 46%), hyperlipidemia (67% vs 40%), heart failure (36% vs 8%), and pericardial effusion (28% vs 2%) than those with ECD-noC. Compared with the matched non-ECD cohort, patients with ECD had higher prevalence of coronary artery disease (20% vs 7%), heart failure (18% vs 4%), and antihypertensive drug use (55% vs 40%). Notably, patients with ECD-C had inferior progression-free survival (PFS) from frontline therapy compared with patients with ECD-noC (5-year PFS, 28.3% vs 70.5%). These findings highlight the burden of CV risk factors and cardiac conditions in ECD, even without a clinical diagnosis of ECD-C. Importantly, this cardiac morbidity burden is substantial for patients with ECD-C compared with ECD-noC. Our findings highlight the need for comprehensive cardiac risk assessment and management strategies to improve patient outcomes.
Depth of Response From Fixed‐Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia
Abeykoon, Jithma P. , Perera, Nirosha D. , Gustine, Joshua , Ramirez‐Gamero, Andres , Varettoni, Marzia , Tedeschi, Alessandra , Cavalloni, Chiara, Frustaci, Anna Maria , Pederson, Levi , Zanwar, Saurabh , Kapoor, Prashant , Kyle, Robert A. , Geyer, Susan M. , Ansell, Stephen M. , Paludo, Jonas , Sarosiek, Shayna , Varettoni, Marzia , Frustaci, Anna Maria , Pederson, Levi D , Zanwar, Saurabh S , Habermann, Thomas , Witzig, T.E. , Gertz, Morie A , Treon, Steven , Castillo, Jorge J , Ansell, Stephen M , Paludo, Jonas , Habermann, Thomas M. , Witzig, Thomas E. , Gertz, Morie A. , Treon, Steven P. , Castillo, Jorge J.

American Journal of Hematology | March 11, 2025 | Volume: 100 | Issue: 6 | Pages: 980-986

10.1002/ajh.27663 Get It

ABSTRACT As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However, the impact of depth of response from fixed‐duration therapy on overall survival (OS) was unclear. This multicenter study evaluated the prognostic impact of depth of response using a landmark survival analysis. A total of 440 patients with WM treated with frontline fixed‐duration regimens were included. Attaining a major response (MaR) was associated with superior outcomes, including significantly longer OS. The estimated 5‐year PFS rates for patients with MaR at 6 months versus not were 50% versus 32%, respectively, p < 0.001, and the estimated 5‐year OS rates for patients with MaR at 6 months versus not were 89% versus 70%, respectively, p < 0.001. In a multivariable analysis, MaR at 6 months was independently associated with superior PFS (HR 0.66, p = 0.007) and OS (HR 0.28, p < 0.001). Similar results were seen when considering deeper responses (CR + VGPR vs. PR). Depth of response at 6 months is an important prognostic marker in WM and an independent predictor of PFS and OS. These results support its utilization as a suitable endpoint in clinical studies in WM.
Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome
Zoref‐Lorenz, Adi , Witzig, Thomas E. , Cerhan, James R. , Jordan, Michael B. , Witzig, T.E. , Cerhan, James R

Leukemia & Lymphoma | December 10, 2024 | Volume: 66 | Issue: 4 | Pages: 628-636

10.1080/10428194.2024.2436037 Get It

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
Bock, Allison M. , Wenzl, Kerstin , Stokes, Matthew E. , Hopper, Melissa A. , Dropik, Abigail R. , Sarangi, Vivek, Ortiz, Maria, Huang, Chuican , King, Rebecca L., Ansell, Stephen M., Gandhi, Anita K. , Nowakowski, Grzegorz S. , Novak, Anne J. , Hopper, Melissa A , Dropik, Abigail R , Wang, Yucai , Witzig, T.E. , Novak, Joseph P. , Krull, Jordan E. , Stong, Nicholas , Maurer, Matthew J. , Farooq, Umar , Wang, Yucai , Witzig, Thomas E. , Ansell, Stephen M. , Habermann, Thomas M. , Cerhan, James R.

Hematological Oncology | November 29, 2024 | Volume: 43 | Issue: 1 | Pages: No page available

10.1002/hon.70006 Get It

ABSTRACTDiffuse large B‐cell lymphoma (DLBCL) patients that fail to achieve a complete metabolic response with frontline immunochemotherapy have a poor prognosis. Genomic profiling has led to a broader understanding of the molecular drivers in DLBCL, but it is unknown how well current classifiers identify patients that will experience primary treatment resistance (PTR). Using whole exome and RNA sequencing data from newly diagnosed DLBCL patients, we evaluated the genomic landscape of PTR and compared it to that of non‐PTR DLBCL. We found a significant increase in the frequency of TP53 (34% vs. 15%, p = 0.005) and ARID1A mutations (21% vs. 7%, p = 0.007) in PTR cases, with pathway analysis further demonstrating a downregulation of TP53 and an increase in chromatin modifying pathways. These results suggest that TP53 and ARID1A may be key mediators of PTR and important pathways contributing to the poor outcomes. We found that the current molecular classifiers were unable to identify PTR cases at diagnosis. However, our newly identified high‐risk signature identified 46% of PTR cases at diagnosis. Overall, these results contribute to our understanding of the genomic landscape of patients with primary treatment resistance.
Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations
Smith, Katherine E. , Dasari, Surendra , Ranatunga, Wasantha , Rech, Karen L. , Ravindran, Aishwarya , McGarrah, Patrick W. , Ruan, Gordon , Zanwar, Saurabh , Sartori‐Valinotti, Julio C. , Snider, Jessica N., Abeykoon, Jithma P. , Smith, Katherine E R , Acosta-Medina, Aldo A, Rech, Karen , McGarrah, Patrick , Ruan, Gordon J , Zanwar, Saurabh S , LI, JENNY J., Sartori-Valinotti, Julio C., Witzig, T.E. , Goyal, Guarav , Go, Ronald S , Abeykoon, Jithma P , Ravindran, Aishwarya , Acosta‐Medina, Aldo A. , Young, Jason R. , Li, Jing , Witzig, Thomas E. , Goyal, Gaurav , Go, Ronald S.

JCO Precision Oncology | November 22, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po-24-00471 Get It

PURPOSE BRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making these treatments less effective. METHODS We describe three patients with histiocytic disorders who have novel non-MAPK pathway alterations. These alterations were studied through genomic and in silico analyses when applicable, then treated with off-label medications rationally selected on the basis of genomic alterations. RESULTS Patient 1 had rapidly progressive ECD involving the CNS. A CSF1R in-frame deletion (p.S560_P566del) was identified, and in silico modeling predicted a gain-of-function mutation. This alteration was targeted with pexidartinib, which led to a clinical complete response (CR) within 2 months, and a partial response (PR) on imaging after 3 months. After 15 months, the disease became resistant to pexidartinib and transformed to histiocytic sarcoma. Patient 2 has skin-only involvement of a xanthogranuloma disorder. A KIF5B-FGFR1 fusion was identified on RNA sequencing and targeted with pemigatinib. At 24 months of follow-up, she remains in a clinical PR. Patient 3 has ECD involving the bone marrow, gastrointestinal tract, and subcutaneous tissues. A MEF2C-FLT3 fusion was identified and targeted with sorafenib. He achieved a clinical CR and radiographic PR within 3 months, which has continued for 30 months. CONCLUSION We report three patients with histiocytic disorders harboring novel alterations who had sustained responses to off-label kinase inhibitors specific to their histiocytic disorder. Pathogenic variants outside of the MAPK pathway, including variants of unknown significant, may be targeted with readily available small molecules.
Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot
Witzig, Thomas E. , Taylor, William R. , Burger, Kelli N. , Devens, Mary E., Arndt, Jacquelyn R., O'Connell, Maria C., Novak, Anne J. , Hennek, Jacquelyn, Katerov, Viatcheslav E. , Allawi, Hatim T. , Dao, Linda N. , Witzig, T.E. , Cerhan, James R , Katerov, Viatcheslav E , Jevremovic, Dragan , Mahoney, Douglas W. , Bamlet, William R. , Foote, Patrick H. , Doering, Karen A. , Berger, Calise K. , Cerhan, James R. , Jevremović, Dragan , Graham, Rondell P. , Kisiel, John B.

American Journal of Hematology | November 20, 2024 | Volume: 100 | Issue: 2 | Pages: 218-228

10.1002/ajh.27533 Get It

ABSTRACT Lymphoma is one of the leading causes of cancer and cancer deaths and yet has not been amenable to population screening. The role of methylated DNA markers (MDMs) in the detection of lymphoma has not been extensively studied. We aimed to discover, validate, and test tissue–derived MDMs of lymphoma in archival plasma specimens. Reduced representation bisulfite sequencing (RRBS) was performed on a discovery set of frozen tissues. MDMs identified were converted to methylation–specific PCR assays and validated on independent formalin–fixed, paraffin‐embedded (FFPE) tissues. Target enrichment long–probe quantitative‐amplified signal (TELQAS) assays were developed and assayed in plasma–extracted, bisulfite‐converted DNA from independent treatment‐naïve lymphoma patients and healthy controls. Prediction of cancer status was modeled using random forest model with in silico cross‐validation. After discovery and validation in tissue, 16 TELQAS assays ( ZNF503 , VWA5B1 , HOXA9 , GABRG3 , ITGA5 , MAX.chr17.7190 , BNC1 , CDK20 , MAX.chr4.4069 , TPBG , DNAH14 , SYT6 , CACNG8 , FAM110B , ADRA1D , and NRN1 ) were selected for testing in plasma. These detected 78% (95% CI, 74%–82%) of lymphoma cases at 90% specificity. Excluding marginal zone and T‐cell lymphomas, sensitivity increased to 84% (80%–88%). MDMs in plasma show promise to detect lymphoma and are candidates for inclusion in multi‐cancer detection studies.
Characteristics and outcomes of incidentally diagnosed diffuse large B‐cell lymphoma and implications for cancer screening
Atallah‐Yunes, Suheil Albert , Mwangi, Raphael , Kuchler, Robyn L., Nowakowski, Grzegorz S. , Habermann, Thomas M. , Wang, Yucai , Thompson, Carrie A. , Maurer, Matthew J. , Ansell, Stephen M. , Rees, Matthew James , Habermann, Thomas , Wang, Yucai , Maurer, Matthew , Cerhan, James R , Ansell, Stephen M , Witzig, T.E. , Atallah-Yunes, Albert , Rees, Matthew J. , Kuchler, Robyn L. , Feldman, Andrew L. , Cerhan, James R. , Witzig, Thomas E.

American Journal of Hematology | October 14, 2024 | Volume: 100 | Issue: 1 | Pages: 158-162

10.1002/ajh.27504 Get It

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations
Xie, Zhuoer , Finke, Christy M. , Amundson, Michelle, McCullough, Kristen , LaPlant, Betsy, Mangaonkar, Abhishek A. , Gangat, Naseema , Reichard, Kaaren K. , Elliott, Michelle A. , Patnaik, Mrinal M. , McCullough, Kristen B , LaPlant, Betsy R, Gangat, Naseema , Witzig, T.E. , Patnaik, Mrinal , Xie, Zhuoer , Fernandez, Jenna , Lasho, Terra L. , Witzig, Thomas E.

Blood | October 1, 2024 | Volume: 144 | Issue: 23 | Pages: 2456-2461

10.1182/blood.2024024962 Get It

Abstract This phase 2 trial assessed high-dose IV ascorbic acid in TET2 mutant clonal cytopenia. Eight of 10 patients were eligible for response assessment, with no responses at week 20 by International Working Group Myelodysplasia Syndromes/Neoplasms criteria. This trial was registered at www.clinicaltrials.gov as #NCT03418038.